Literature DB >> 19356608

Chimeric hepatitis B and C viruses envelope proteins can form subviral particles: implications for the design of new vaccine strategies.

Romuald Patient1, Christophe Hourioux, Pascal Vaudin, Jean-Christophe Pagès, Philippe Roingeard.   

Abstract

The hepatitis B virus (HBV) envelope protein (S) self-assembles into subviral particles used as commercial vaccines against hepatitis B. These particles are excellent carriers for foreign epitopes, which can be inserted into the external hydrophilic loop or at the N- or C-terminal end of the HBV S protein. We show here that the N-terminal transmembrane domain (TMD) of HBV S can be replaced by the TMDs of the hepatitis C virus (HCV) envelope proteins E1 and E2, to generate fusion proteins containing the entire HCV E1 or E2 sequence that are efficiently coassembled with the HBV S into particles. This demonstrates the remarkable tolerance of the HBV S protein to sequence substitutions conserving its subviral particle assembly properties. These findings may have implications for the design of new vaccine strategies based on the use of HBV subviral particles as carriers for various transmembrane proteins and produced using the same industrial procedures that are established for the HBV vaccine.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19356608     DOI: 10.1016/j.nbt.2009.01.001

Source DB:  PubMed          Journal:  N Biotechnol        ISSN: 1871-6784            Impact factor:   5.079


  19 in total

1.  Hepatitis B virus surface antigen assembly function persists when entire transmembrane domains 1 and 3 are replaced by a heterologous transmembrane sequence.

Authors:  Ira Berkower; Angelo Spadaccini; Hong Chen; Danah Al-Awadi; Jacqueline Muller; Yamei Gao; Dino Feigelstock; Konstantin Virnik; Yisheng Ni
Journal:  J Virol       Date:  2010-12-22       Impact factor: 5.103

Review 2.  Progress in the development of vaccines for hepatitis C virus infection.

Authors:  Faezeh Ghasemi; Sina Rostami; Zahra Meshkat
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

3.  Role of transmembrane domains of hepatitis B virus small surface proteins in subviral-particle biogenesis.

Authors:  Vera D Siegler; Volker Bruss
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

Review 4.  Host factors involved in hepatitis B virus maturation, assembly, and egress.

Authors:  Reinhild Prange
Journal:  Med Microbiol Immunol       Date:  2012-09-11       Impact factor: 3.402

Review 5.  Prospects for prophylactic hepatitis C vaccines based on virus-like particles.

Authors:  Elodie Beaumont; Philippe Roingeard
Journal:  Hum Vaccin Immunother       Date:  2013-02-13       Impact factor: 3.452

Review 6.  Status of hepatitis C virus vaccination: Recent update.

Authors:  Kouka Saadeldin Abdelwahab; Zeinab Nabil Ahmed Said
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

Review 7.  To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity.

Authors:  Felicia Schlotthauer; Joey McGregor; Heidi E Drummer
Journal:  Viruses       Date:  2021-04-30       Impact factor: 5.048

8.  Chimaeric virus-like particles derived from consensus genome sequences of human rotavirus strains co-circulating in Africa.

Authors:  Khuzwayo C Jere; Hester G O'Neill; A Christiaan Potgieter; Alberdina A van Dijk
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

9.  A novel platform for virus-like particle-display of flaviviral envelope domain III: induction of Dengue and West Nile virus neutralizing antibodies.

Authors:  Anthony J S Chua; Cyrielle Vituret; Melvin L C Tan; Gaëlle Gonzalez; Pierre Boulanger; Mah-Lee Ng; Saw-See Hong
Journal:  Virol J       Date:  2013-04-24       Impact factor: 4.099

Review 10.  Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies.

Authors:  Catherine Fauvelle; Che C Colpitts; Zhen-Yong Keck; Brian G Pierce; Steven K H Foung; Thomas F Baumert
Journal:  Expert Rev Vaccines       Date:  2016-06-13       Impact factor: 5.683

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.